AUG 28, 2018 09:58 PM PDT

Combination Therapy for Advanced Melonoma

WRITTEN BY: Nouran Amin

Image: Cancer Research UK

According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with advanced melanoma; an aggressive skin cancer. The research examined the molecular actions of an immunotherapy drug pembrolizumab and the bacterial agent SD-101 (a pattern of nucleic acids imitating a bacterial infection) on their alteration of microenvironment enclosing a tumor. The alteration enabled the immune system to effectively increase its attack on cancer.

The immunotherapeutic drug, pembrolizumab, marketed under the brand name ‘Keytruda’, worked by inhibiting PD-1, which is a protein that exerts actions on the function of the immune system. Inhibiting PD-1 with pembrolizumab allowed the immune system cells to better recognize cancer. While Pembrolizumab is actually known for treating people with advanced or metastatic cancers, however, the majority of metastatic melanoma tumors resisted the effects of the drug. "We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready," explained Dr. Antoni Ribas, lead author, professor of medicine at UCLA’s David Geffen School of Medicine, and director UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program. "So we thought, 'What if we change that by injecting the therapeutic drug into the metastatic lesions and change the microenvironment of the cancer? It's like having a pile of wood but not having a match to light it. With this new approach, SD-101 is the match that starts the fire."

Image: NorthShore.org

Interestingly, scientists discovered that SD-101 not only orchestrates T cells to cancer cells but also ensures the microenvironment is appropriate for T cells; allowing them to eradicate cancer cells. "For all patients with advanced cancer, immunotherapy using PD-1 inhibitors has really changed the face of cancer treatment. Unfortunately, this therapy still only works in a subset of patients," says Dr. Deborah Wong, author of the study and oncologist at the Ronald Reagan UCLA Medical Center. "This particular combination has been especially gratifying because not only does the SD-101 therapy drug induce tumor shrinkage at the actual site where it's injected, but it's working in conjunction with pembrolizumab to shrink tumors outside of the ones we're directly injecting."

The following study highlights the urge for more research behind combination therapies especially since many cancer patients do not readily respond to immunotherapy and often experience a reoccurrence of tumors post-treatment.

"We are really starting to understand the science of how immunotherapies work in patients," explained Ribas. “By understanding that, we can find more ways to make that therapy more active. One way is by combining the therapy with another agent that can overcome the resistance that some cancers have to these therapies."

Watch the video below to learn more about Melanoma!

Source: University of California - Los Angeles Health Sciences, Cancer Discovery

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
OCT 31, 2018
Drug Discovery
OCT 31, 2018
Cytostatic Drug Proved Potent For Cancer
A study published in journal Angewandte Chemie, describes how a cytostatic drug, consisting of therapeutically active molecules that is linked to specific ...
NOV 13, 2018
Cell & Molecular Biology
NOV 13, 2018
The Mechanism of a Cell-penetrating Peptide is Revealed
Cells have a barrier around them, which carefully controls what can move across it. That presents a challenge in pharmaceutical design....
NOV 24, 2018
Drug Discovery
NOV 24, 2018
New Anti-Malarial Drug Target in Cancer
For decades, anti-malaria drugs--known as Chloroquines, have used to treat cancer. But the role in repurposing these drugs for slowing tumor growth have ne...
NOV 25, 2018
Drug Discovery
NOV 25, 2018
'Longevity protein' Improves Healing in Aging Muscles
A downside to aging is that the skeletal muscles lose their ability to heal after muscle injury. However, a recent research study at the University of Pitt...
DEC 17, 2018
Drug Discovery
DEC 17, 2018
Nanocapsules Improve The Delivery of Antiparasitic Drugs
The efficacy of antiparasitic medications highly depends on how they dissolve and are absorbed by the body—limiting the therapeutic potential of trad...
Loading Comments...